Is Kenvue (KVUE) A Bargain Following Its TYLENOL With Naproxen Launch?

Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...